Phio Pharmaceuticals Corp.

NasdaqCM:PHIO Stock Report

Market Cap: US$3.1m

Phio Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bob Bitterman

Chief executive officer

US$437.9k

Total compensation

CEO salary percentage86.8%
CEO tenure1.2yrs
CEO ownership0.3%
Management average tenureno data
Board average tenure6.8yrs

Recent management updates

Recent updates

Phio Pharmaceuticals appoints interim executive chairman

Sep 29

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Aug 11

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

Nov 09

CEO Compensation Analysis

How has Bob Bitterman's remuneration changed compared to Phio Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$438kUS$380k

-US$11m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022US$173kUS$32k

-US$11m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$78kn/a

-US$13m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$45kn/a

-US$9m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$64kn/a

-US$9m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$53kn/a

-US$7m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$9m

Mar 31 2018n/an/a

-US$9m

Dec 31 2017US$36kn/a

-US$12m

Compensation vs Market: Bob's total compensation ($USD437.89K) is below average for companies of similar size in the US market ($USD673.36K).

Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.

CEO

Bob Bitterman (72 yo)

1.2yrs

Tenure

US$437,892

Compensation

Mr. Robert J. Bitterman, also known as Bob, serves as Chairman at Phio Pharmaceuticals Corp. since 2012 and has been its President and Chief Executive Officer since February 20, 2023. Mr. Bitterman served...

Board Members

NamePositionTenureCompensationOwnership
Robert Bitterman
President11.8yrsUS$437.89k0.29%
$ 9.1k
Patricia Bradford
Independent Director2yrsUS$57.86k0.069%
$ 2.1k
Curtis Lockshin
Independent Director11yrsUS$50.36k0.070%
$ 2.2k
Robert Ferrara
Lead Independent Director4.5yrsUS$70.36k0.087%
$ 2.7k
Jonathan Freeman
Independent Director6.8yrsUS$42.86k0.070%
$ 2.2k

6.8yrs

Average Tenure

71yo

Average Age

Experienced Board: PHIO's board of directors are considered experienced (6.8 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.